EyePoint reports Q4/FY2023 results; positive Phase 2 data for EYP-1901 in wet AMD

EyePoint, Inc.

Q4 net loss $14.1M ($0.33/sh) vs $43.5M ($1.16/sh) YoY; total net revenue $14.0M (+33%).
Cash and investments $331M as of Dec 31, 2023, funding operations through Phase 3 topline data for wet AMD in 2026.
Positive Phase 2 DAVIO 2 data: EYP-1901 met all primary/secondary endpoints; first Phase 3 trial expected 2H 2024.
First patient dosed in Phase 2 VERONA trial for DME; topline data 1Q 2025; PAVIA NPDR data expected 2Q 2024.
Appointed Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

EyePoint, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.

Period: the fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 7, 2024, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023 and certain other information.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

EyePoint, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-027582

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.